Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...

Avalo Therapeutics (NASDAQ:AVTX) stock rises as Cantor Fitzgerald launches coverage with an Overweight rating, highlighting its lead asset, AVTX-009. Read more here.

The study also noted a 15% drop in substance misuse and showed benefit for patients who were taking stimulant medications rather than nonstimulants. Plus: developing new painkillers; how semaglutide ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

The dermatology team at Zulekha Hospital is trained in the latest biological therapies ...

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

Hidradenitis suppurativa patients face higher depression and anxiety risks, but biologic treatments may reduce these mental ...

Insmed’s recent earnings call reflected a positive outlook, underscored by strong performance across its late-stage and early-stage portfolios. The company reported record ARIKAYCE revenue and ...